AHPA Statement on oleandrin and Nerium oleander

Market Alerts

November 2021

  • SCNM Dedicates Ric Scalzo Institute of Botanical Research
  • August 2021

    July 2021

    March 2021

    February 2021

    November 2020

    October 2020

    September 2020

    August 2020

    July 2020

    June 2020

    April 2020

    February 2020

    January 2020

  • Sabinsa's parent company Sami Labs breaks ground on $30 million state of the art production facility
  • Unstoppable Moms Across America launches new Gold Standard to shift the marketplace for a healthier planet
  • Draco Achieves Safe Quality Food (SQF) certification of its manufacturing facilities
  • August 2019

    June 2019

    May 2019

    March 2019

    February 2019

    January 2019

    December 2018

    November 2018

    October 2018

    September 2018

    August 2018

    July 2018

    May 2018

    April 2018

    March 2018

    February 2018

    January 2018

    December 2017

    November 2017

    October 2017

    September 2017

    August 2017

    July 2017

    June 2017

    AHPA Statement on oleandrin and Nerium oleander

    AHPA strongly discourages sales or marketing of dietary supplements that contain any part of the oleander plant

    Published: Tuesday, August 18, 2020

    Over the last few days, the potential use of oleandrin for treatment of COVID-19 has received significant media attention.

    The American Herbal Products Association (AHPA) strongly discourages sales or marketing of dietary supplements that contain any part of the oleander plant (Nerium oleander) or its constituent, oleandrin. AHPA also urges physical and online retailers to refrain from offering any such products for sale, and AHPA cautions consumers to avoid oral consumption of oleander or oleandrin.

    Oleandrin is a cardiac glycoside found in the oleander plant. Oleander is a highly toxic plant, and death has been associated with oral ingestion of even small amounts of oleander leaf.

    Of particular interest to dietary supplement marketers, a new dietary ingredient (NDI) notification was submitted to the Food and Drug Administration (FDA) for an oleander extract in 1998. FDA responded to this notification by noting, in part, “All parts of the oleander plant are poisonous to man and animals … [due to] the cardiac glycosides in oleander … [including] oleandrin….” In reviewing the NDI notification records, AHPA notes it is exceedingly rare for the agency to essentially reject a notification due to known safety concerns. Indeed, among the responses to the more than 1,000 NDI notifications released by FDA to date, AHPA identified only seven expressing known safety concerns in this manner.

    AHPA advises that anyone who believes they may have contracted COVID-19 should contact a healthcare professional immediately. The Centers for Disease Control and Prevention has more information on the novel coronavirus and the proper actions to take if you suspect you are ill.

    Print

    2021 Annual Fund Sponsors

        

    AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.